BioMarin's Voxzogo Meets Goal in Late-Stage Study for HypochondroplasiaZacks Investment Research • 05/21/26
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with HypochondroplasiaPRNewsWire • 05/20/26
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 DeficiencyPRNewsWire • 05/18/26
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedZacks Investment Research • 05/05/26
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/05/26
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual MeetingPRNewsWire • 05/02/26
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ETPRNewsWire • 04/27/26
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A BuySeeking Alpha • 04/15/26
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/25/26
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPRNewsWire • 03/12/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/09/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26